CRDF vs DGX · rev $145.0K vs P/E 22, rev $5.94B
Cardiff Oncology Inc (CRDF) versus Quest Diagnostics Incorporated (DGX) — a side-by-side from cached financials, not a winner call.
Cardiff Oncology Inc (CRDF) is a biotechnology company listed on US.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Latest reported CRDF revenue for 2026-06-30 was $145.0K. Net income was -$21.6M. CRDF currently screens at market cap $238.8M.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
CRDF currently screens at market cap $238.8M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Not investment advice. Open the CRDF and DGX stock pages for the full models.
Not investment advice.